183 results about "L-S DISEASE" patented technology

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and / or Multiple Sclerosis.

Aspects of the disclosure relate to methods and compositions (e.g., kits) for detecting anti-repeat-associated non-ATG (RAN) protein antibodies in a subject (e.g., a subject that has been administered a therapeutic anti-RAN protein antibody or a vaccine against a disease or disorder associated with RAN protein expression, translation, and / or accumulation, for example amyotrophic lateral sclerosis (ALS) and / or frontotemporal dementia (FTD)). In some embodiments, methods described by the disclosure comprise detecting one or more anti-RAN protein antibodies in a biological sample obtained from a subject by an electrochemiluminescence-based immunoassay using one or more target di-amino acid repeat peptides. In some embodiments, the disclosure relates to kits comprising one or more di-amino acid repeat peptides and an electrochemiluminescence-based immunoassay plate and / or reagents.

The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.

The invention discloses an application of serratia marcescens in preparation of a medicine for preventing or treating gradual freezing (amyotrophic lateral sclerosis, ALS) or frontotemporal dementia (FTD). Specifically, the serratia marcescens of the present invention can improve the phenotype of an asymptomatic and frontotemporal dementia model S59L by reducing mitochondrial unfolded protein response (UPRmt); meanwhile, expression of excitatory amino acid glutamic acid can be reduced, excitatory neurotoxicity can be relieved, and ALS and FTD phenotypes can be relieved through cooperation of the two.

Aspects of the disclosure relate to compositions and methods for the diagnosis and / or treatment of certain neurodegenerative diseases, for example those diseases associated with repeat-associated non-ATG (RAN) translation proteins, such as amyotrophic lateral sclerosis (ALS). In some embodiments, the disclosure relates to recombinant adeno-associated viruses (rAAVs) expressing antibodies and antigen-binding fragments thereof that bind to poly(GA) RAN proteins. In some embodiments, the disclosure relates to methods of treating a RAN protein-associated disease by administering to a subject in need thereof the rAAVs.

The present application relates to siRNA and oligonucleotide agents for use in the prevention or treatment of SOD1-related neurodegenerative diseases or conditions, such as amyotrophic lateral sclerosis, ALS. The oligonucleotide agent comprises a double-stranded targeting oligonucleotide (siRNA) and a non-targeting single-stranded oligonucleotide (ACO), wherein the siRNA targets the mRNA region of the target gene SOD1.

The invention discloses a tomography and targeted energy thermal therapy system and method based on an acousto-optic coupling functional film layer, and relates to the technical field of noninvasive medical diagnosis and treatment. The system comprises an intelligent processing carrier, an acousto-optic coupling function film layer, a scanning mechanism, an energy treatment module and a processing and temperature control module. The intelligent processing carrier at least comprises a 20Hz-20kHz audio unit, a pickup unit, an optical signal unit and a processor; the acousto-optic coupling functional film layer is of a single physical structure and is inseparable, acoustic frequency conversion focusing imaging and targeted warm delivery at 42-47 DEG C are achieved in the same physical area in a time-sharing mode, the acoustic processing layer achieves 1000-8000 frequency doubling through a multi-stage resonance microcavity array, and the echo signal-to-noise ratio is larger than or equal to 15 dB; the scanning mechanism comprises a plurality of modes such as rotation, translation, multi-device array, human body movement, local limb movement, human body bearing support device movement and the like; the energy forms cover all types of light, electromagnetism, radio frequency and the like capable of generating a warm effect, including but not limited to non-contact or contact energy delivery modes. The traditional Chinese medicine composition is suitable for tumors, infections, inflammations, and all lesions sensitive to temperature of 42-47 DEG C including nervous system lesions such as amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, multiple sclerosis and the like, is low in cost, free of radiation and easy to popularize, and has extremely high creativity and practical value.

The invention discloses an editing system for repairing amyotrophic lateral sclerosis pathogenic mutant genes, and relates to an IS621-bridge-RNA gene editing system capable of being applied to eukaryotic cells, an AAV9 virus vector mediated IS621-bridge-RNA gene editing system and application of the AAV9 virus vector mediated IS621-bridge-RNA gene editing system, and the IS621-bridge-RNA gene editing system, a recombinant expression vector and a gene therapy mode are included.

An object of the present invention is to provide a therapeutic or preventive agent for amyotrophic lateral sclerosis, the agent having inhibitory action against ferroptosis. The present invention provides a therapeutic or preventive agent for amyotrophic lateral sclerosis, the agent containing a tetrahydroquinoline derivative represented by the compound below or a pharmaceutically acceptable salt thereof as an active ingredient.

The present invention belongs to the technical field of medicine. Disclosed are a class of magnolol / honokiol derivatives, a preparation method therefor, a pharmaceutical composition thereof and the use thereof. Specifically, disclosed in the present invention are magnolol / honokiol nitrone derivatives as represented by general formulas (I) and (II). Such derivatives are prepared by means of artificial synthesis. Further provided are a pharmaceutical composition containing same, and the use thereof against inflammation, against cerebral infarction, in the treatment of amyotrophic lateral sclerosis, and against cerebral trauma.

To provide stabilization of a retromer for treating Alzheimer disease and other neurodegenerative disorders.SOLUTION: Provided is a method and a composition for increasing and stabilizing a retromer in order to treat and / or prevent Alzheimer disease and other neurodegenerative disorders. Furthermore, provided is treatment of an adenovirus base for treating Alzheimer disease (AD), and other neurodegenerative states, which are Parkinson disease (PD), neuronal ceroid lipofuscinosis (NCL), and transmissible spongiform encephalopathy (TSE or prion disease), multiple system atrophy (MSA), Down syndrome, and hereditary spastic paraplegia for example, and which are progressive supranuclear palsy (PSP), frontotemporal dementia linked to chromosomes 17q21 to 22 and subtype (FTLD-17 / FTLD-Tau) thereof, Lewy body disease (LBD), amyotrophic lateral sclerosis (AES), frontotemporal degeneration (FTD), ALS-FTD and chronic traumatic encephalopathy (CTE) for example.SELECTED DRAWING: None

To provide a C9orf72 oligonucleotide, a composition, and a method for treatment of C9orf72-associated conditions, disorders, or diseases including amyotrophic lateral sclerosis and frontotemporal dementia.SOLUTION: Provided is an oligonucleotide comprising at least one modification of a sugar, a base, or an internucleotidic linkage, wherein the base sequence of the oligonucleotide is or comprises at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 contiguous bases of a base sequence that is at least 80% identical with or complementary to a base sequence of a C9orf72 gene or a transcript thereof, and wherein a nucleobase at a 3' end of the oligonucleotide is optionally replaced by a replacement nucleobase selected from I, A, T, U, G, and C.SELECTED DRAWING: None

Disclosed herein are compounds and methods of use thereof effective for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), a disease that affects nerve cells in the brain and spinal cord, eventually causing loss of muscle strength. The compounds of the disclosure include, cutamesine, a synthetic sigma receptor agonist selective for the 81 receptor, and also a chaperone protein of the central nervous system that plays a key role in the modulation of calcium ions and apoptosis, as well as a sapogenin, such as smilagenin, a non-peptide neurotrophic factor that aids in the reversal of free radical neurotoxicity.

To provide an agent for treating or preventing amyotrophic lateral sclerosis.SOLUTION: This agent for treating or preventing amyotrophic lateral sclerosis essentially comprises at least one active ingredient selected from the group consisting of cycloserine and terizidone, and salts thereof. The active ingredient may be at least one selected from the group consisting of cycloserine and terizidone, and salts thereof. The cycloserine may be D-cycloserine. The cycloserine may be L-cycloserine.SELECTED DRAWING: Figure 8

Provided are pharmaceutical formulations and dosing regimen for antibody-based treatment of amyotrophic lateral sclerosis (ALS).

The present disclosure provides compositions and methods for modulating C9orf72 gene transcription in patients in need thereof, including patients suffering from C9orf72 related diseases, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

The present disclosure provides herein, inter alia, methods of treating patients diagnosed with amyotrophic lateral sclerosis (ALS).

A compound nitarsone, or salt thereof is provided for use in the treatment of a neurodegenerative disease, such as Alzheimer's disease (AD), dementia, Parkinson's disease (RD) or amyotrophic lateral sclerosis (ALS). A pharmaceutical composition is also provided that includes compound, or salt thereof for use in the treatment of a neurodegenerative disease.

The invention discloses application of 20-Deacetyltaxupine X in preparation of a medicine for preventing and / or treating amyotrophic lateral sclerosis, and belongs to the technical field of medicinal chemistry. The novel serine-threonine kinase CDC7 inhibitor and CDC7 form a new hydrogen bond, and guidance is provided for design of CDC7 inhibitor drugs. The novel serine-threonine kinase CDC7 inhibitor has a protection effect on an amyotrophic lateral sclerosis cell model, and can be used as an amyotrophic lateral sclerosis resisting medicine. The novel serine-threonine kinase CDC7 inhibitor has a protective effect by inhibiting apoptosis of an amyotrophic lateral sclerotic cell model.

Provided herein are methods and compositions for blocking integrin subunit beta 8 (ITGB8, also known as integrin alpha v beta 8) to treat neurodegenerative diseases associated with microglial cell injury, including Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS).

A compound represented by General Formula (I) or a salt thereof; a nerve growth promoter comprising the compound or the salt thereof as an active ingredient; a pharmaceutical composition comprising the compound or the salt thereof; a therapeutic agent for neurodegenerative diseases comprising the compound or the salt thereof as an active ingredient; a therapeutic agent for amyotrophic lateral sclerosis comprising the compound or the salt thereof as an active ingredient; a therapeutic agent for pain comprising the compound or the salt thereof as an active ingredient; and a therapeutic agent for lower urinary tract dysfunction comprising the compound or the salt thereof as an active ingredient.

The disclosure provides methods for (i) treating multiple sclerosis in patient, (ii) treating a patient having symptoms of multiple sclerosis, (iii) preventing the onset of multiple sclerosis symptoms in patient having multiple sclerosis or predisposed to multiple sclerosis; (iv) promoting or enhancing immunomodulation and remyelination and / or myelin repair in a subject in need thereof; (v) a neuroinflammatory disorder; (vi) Amyotrophic Lateral Sclerosis; or (vii) a demyelinating disease or disorder or a hypomyelinating condition, each method comprising administering a therapeutically effective amount of a bryostatin compound to the patient.

The traditional Chinese medicine comprises (1) radix puerariae, (2) radix angelicae sinensis, (3) radix salviae miltiorrhizae, (4) radix codonopsis, (5) radix astragali, (6) fructus perillae, (7) fructus ziziphi jujubae, (8) radix bupleuri, (9) radix scutellariae, (10) flos carthami, (11) radix curcumae, (12) radix et rhizoma rhei, (13) pericarpium zanthoxyli, (14) radix glycyrrhizae, (15) radix ophiopogonis, (16) fructus schizandrae, (17) radix aconiti carmichaeli, (18) radix ginseng, (19) poria cocos, (20) gypsum, (21) oyster, (22) cassia twig and (23) semen plantaginis. Or extracts of the above components, the amount of the extracts being equivalent to the amount of the raw materials of the corresponding components. The invention aims at the clinical curative effect of amyotrophic lateral sclerosis diseases with different pathological manifestations. The medicine can be combined with western medicines for use.

The invention discloses a construction method and application of a zebra fish model. The construction method comprises the following steps: taking zebra fish as a model animal, and obtaining a zebra fish model by knocking out a sod1 gene in the zebra fish and / or expressing a human source sod1 gene mutant in the zebra fish; wherein the serial number of the sod1 gene in the zebra fish in an Ensepbl database is ENSDARG00000043848, and the nucleotide sequence of the human source sod1 gene mutant is as shown in SEQ ID NO. 1. The zebrafish can be used for the function research of the sod1 gene in the zebrafish, the function research of the human-derived sod1 gene mutant, the pathological research of amyotrophic lateral sclerosis and the screening of amyotrophic lateral sclerosis resisting drugs.

Disclosed are compositions and / or methods of use of the compositions for patients with neuronal diseases such as AD, Parkinson's, Huntington's, multiple sclerosis, and ALS. In certain embodiments flavonoids alone, or in a pharmaceutical preparation, are administered through the nasal olfactory route. In certain embodiments the flavonoid is apigenin and the neural disease is Alzheimer's. In some embodiments a porosome complex is administered for reconstitution into a neural cell. In certain embodiments, a co-administered blood-brain barrier traversing peptide is configured as a mimic of a domain of ATP 1 A3 and / or Tubulin.

The present invention relates to splice variants of the CERT1 protein that act as biomarkers for TDP-43 pathology, particularly motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), as well as other neurological diseases such as Alzheimer's disease. In particular, the present invention relates to a method for identifying splice variants of CERT1 comprising cryptic peptide sequences, as well as related methods for identifying TDP-43 pathology and / or TDP-43 dysfunction in a subject, and a method for predicting the likelihood of successful treatment. Antibodies that bind to CERT1 splice variants and kits comprising said antibodies are also claimed.

The present disclosure relates, in part, to the selective inhibition of JUN N-terminal kinase (JNK1, JNK2, and / or JNK3; the present invention relates to compounds of formulae (I) and (II), which are also known as MAPK8, MAPK9 and / or MAPK10), pharmaceutical compositions thereof and methods of their use for treating, preventing and / or ameliorating one or more diseases and / or disorders in a subject. In certain embodiments, the inflammatory disease or disorder is endometriosis, arthritis, pulmonary fibrosis, cancer, type 1 and / or type 2 diabetes, Alzheimer's disease, Parkinson's disease, or amyotrophic lateral sclerosis. In certain embodiments, the methods described herein further comprise detecting a disease and / or disorder in a subject with a suitable diagnostic method.

The invention provides a benzylimidazole glutamine cyclase inhibitor as well as a preparation method and application thereof, and belongs to the field of medical chemistry. The compound as shown in the formula I is prepared, the compound has good inhibitory activity on glutamine cyclase, and the half inhibitory concentration of most compounds reaches the nanomole level; the compound has a wide application prospect in preparation of drugs for treating Alzheimer's disease, depression, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, tumor, synovial membrane disease, gout, acute / chronic enteritis, rheumatoid arthritis or inflammatory diseases, and lays a material basis for research and development of related drugs.

The invention belongs to the field of early screening of diseases, and particularly relates to application of a protein marker in preparation of a product for early screening, identification and diagnosis of amyotrophic lateral sclerosis. The expression of LanCL1 in serum of ALS patients is higher than that in serum of healthy people and is negatively related to the state of illness, and the marker has no abnormality in Parkinson's disease patients and is high in specificity. The product is a blood detection kit, sampling is convenient, patient compliance is good, early diagnosis, identification and illness state evaluation of ALS can be achieved, and the problems that an existing marker is insufficient in specificity and complex in sampling are solved.